Hydration Failed to Move the Needle in the PUSH Kidney Stone Trial
Kidney stone prevention still turns on one deceptively simple instruction: drink more. Yet the latest randomized evidence shows how difficult that advice is to convert into a meaningful biologic effect. In the Prevention of Urinary Stones With Hydration trial, a behavioral program designed to increase fluid intake produced only a modest rise in urinary volume and did not significantly reduce stone recurrence over 2 years compared with standard care.
The result matters because hydration remains the most familiar, least toxic, and least expensive preventive strategy in nephrolithiasis. It also exposes a familiar gap between physiologic plausibility and real-world execution. Diluting urinary supersaturation should, in principle, reduce crystal formation and growth. In practice, the intervention has to be large enough, sustained enough, and consistent enough to shift the renal milieu over time.
A Large Trial, a Small Separation Between Arms
The trial enrolled 1658 patients and tested whether a behavioral approach could reliably increase urine output enough to reduce recurrent stone disease. Instead, the separation between the intervention group and the control group remained small. Urinary volume increased, but not by enough to translate into a statistically significant clinical advantage over 2 years.
One sentence captures the central problem: the active arm drank more, but not enough more.
That limited gap in output is clinically important. Stone recurrence depends on the cumulative effect of urinary concentration over time, not just on occasional adherence at a clinic visit or during a short stretch of heightened motivation. When the difference in urine volume is modest, the expected reduction in supersaturation may never become large enough to alter event rates in a detectable way.
Why Earlier Successes Do Not Disappear Here
These findings do not erase the physiologic basis for hydration. They sit uneasily beside the earlier Borghi trial from 1996, where sustained urine output above 2 L/day significantly reduced stone recurrence. The contrast is instructive rather than contradictory. The older trial achieved a more durable and more substantial change in urine volume, and that degree of exposure appears to be the threshold at which the renal environment becomes less permissive for stone formation.
The PUSH trial instead suggests that the efficacy of hydration is contingent on dose, duration, and adherence. A marginal increase in fluid intake may sound favorable on paper, but stone disease responds to chemistry, not intention. Urinary supersaturation has to fall enough to change crystal nucleation and aggregation, and the biology does not reward small, intermittent gains.
Adherence Problems Framed the Null Result
The most plausible explanation for the neutral outcome is insufficient adherence. The report points to a minimal difference in urine output between the two groups, which weakens any expectation of a clinical separation. In a prevention trial built around behavior, the biologic target is only as strong as the patient’s ability to maintain the intervention in daily life.
Functional urinary symptoms may have interfered with compliance. Patients asked to increase fluid intake often face a practical tradeoff: more drinking means more voiding, more urgency, and more disruption of work, sleep, travel, and social routines. For some individuals, especially those already burdened by urinary symptoms, the instruction to hydrate can become difficult to sustain in the ordinary settings where prevention has to succeed.
Social constraints likely played a role as well. Access to bathrooms, job demands, commuting patterns, and fear of urinary urgency can all blunt adherence. Those pressures rarely appear in a lab value, yet they shape whether a preventive strategy reaches the renal tubule at all.
Standard Care May Have Narrowed the Contrast
Another reason the treatment effect may have been hard to detect is that control-group management has improved. The control arm may no longer represent an untreated historical baseline in the way it once did. Better routine counseling, greater awareness of stone prevention, and more structured background management can all reduce event rates in standard care and shrink the apparent benefit of an additional behavioral program.
This is the familiar challenge of contemporary prevention trials: when usual care gets better, incremental strategies have to work harder to prove themselves. A modest intervention layered on top of improved counseling may be biologically reasonable but still too weak to separate clearly in a modern cohort.
What Stone Prevention Still Requires at the Bedside
The clinical message is not that hydration is useless. The message is that hydration alone, delivered as a behavioral suggestion, may be too imprecise to change outcomes unless it produces a substantial and sustained increase in urine volume. Preventive care for recurrent stone formers likely needs a more complete strategy: dietary measures, pharmacologic treatment when indicated, and repeated reinforcement of fluid goals that are realistic enough to maintain.
For clinicians, the practical question is not whether to recommend fluids. It is whether the patient can reach a urine volume high enough to matter and keep it there. That requires follow-up, patient-specific counseling, and attention to the barriers that turn a sensible recommendation into an unworkable one.
The trial also reinforces a broader principle in nephrology: mechanism is not enough. A treatment can be safe, inexpensive, and physiologically coherent, yet still fail if the delivered dose is too small or the adherence burden too high. Hydration remains central to stone prevention, but the PUSH experience shows that the path from advice to outcome is much longer than it looks.
The Threshold Problem in Urinary Stone Prevention
The older evidence base points toward a threshold effect. Below a certain level of urine output, the urinary environment may remain concentrated enough for crystals to form; above it, recurrence falls. PUSH did not appear to generate a robust enough shift across that threshold. The result is a neutral recurrence signal despite some movement in urinary volume.
That pattern should sharpen future trial design. Prevention studies in kidney stone disease will likely need interventions that do more than encourage drinking. They may need tools that monitor adherence more directly, address urinary symptoms that limit compliance, and combine hydration with broader metabolic management. Without that, a safe intervention can remain scientifically credible while still being clinically underpowered in the real world.
For now, the trial leaves one concrete conclusion: increasing urine volume remains biologically sound, but behavioral encouragement alone may not reliably produce the magnitude of change required to prevent recurrent stones over 2 years.